Donenberg Phillip B.
Known title: DirectorCIK: 0001238120
Donenberg Phillip B.'s purchase track record
Donenberg Phillip B. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2023 | TSHA | $100K | -13.0% | -24.3% | +13.5% |
| 2/2/2022 | TSHA | $23K | -44.3% | -43.3% | -9.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TSHA | ▲ Buy | Grant | 21,335 | $0 | 6/1/2026 | View on chart |
| TSHA | ▲ Buy | Grant | 56,623 | $0 | 6/2/2025 | View on chart |
| TSHA | ▲ Buy | Grant | 49,220 | $0 | 5/29/2024 | View on chart |
| TSHA | ▲ Buy | Open Market | 111,111 | $100K | 8/16/2023 | View on chart |
| TSHA | ▲ Buy | Open Market | 3,000 | $23K | 2/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views
Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.